Patents Assigned to Daiichi Sankyo Company, Limited
  • Patent number: 10654821
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: May 19, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Patent number: 10647769
    Abstract: To provide a novel antibody. Provided is a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.
    Type: Grant
    Filed: November 7, 2019
    Date of Patent: May 12, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Ryuta Mukasa, Kensuke Nakamura, Sumie Muramatsu, Naoyuki Makita
  • Publication number: 20200131230
    Abstract: Provided is a compound that can promote angiogenesis by inhibiting the function of TSP1, and is useful for the treatment or prophylaxis of diseases such as critical limb ischemia.
    Type: Application
    Filed: September 13, 2017
    Publication date: April 30, 2020
    Applicants: Daiichi Sankyo Company, Limited, PeptiDream Inc.
    Inventors: Takahiro YAMAGUCHI, Yutaka MORI, Hironao SAITO, Hideki KUBOTA, Akihiro FURUKAWA, Eri OTSUKA, Yutaka ISHIGAI, Hiroshi IJIRI, Patrick REID
  • Patent number: 10633346
    Abstract: A method for producing a compound (4), which comprises allowing a compound (1) to react with hydrogen gas in an inert solvent, in the presence of a specific chiral ligand and a ruthenium catalyst, or in the presence of an asymmetric transition metal complex catalyst previously generated from the chiral ligand and the ruthenium catalyst.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: April 28, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Masaki Hayashi, Kazutoshi Ukai
  • Publication number: 20200123253
    Abstract: To provide a novel antibody. Provided is a monoclonal antibody or a binding fragment thereof that binds to domain 3 of human LAG-3 and has one or more of the properties described in (ii) to (v), and the properties described in (i) and (vi) below: (i) having in vitro ADCC activity; (ii) reducing the number of LAG-3 positive cells in vivo in low fucose form; (iii) suppressing experimental autoimmune encephalomyelitis in vivo in low fucose form; (iv) binding to human activated T cells; (v) human LAG-3 binds to human major histocompatibility complex class II molecules in the presence of the antibody or the binding fragment thereof; and (vi) the presence of the antibody or the binding fragment thereof allowing human LAG-3 to exert a human T cell suppression function.
    Type: Application
    Filed: November 7, 2019
    Publication date: April 23, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Ryuta Mukasa, Kensuke Nakamura, Sumie Muramatsu, Naoyuki Makita
  • Publication number: 20200115446
    Abstract: An object of the present invention is to provide a pharmaceutical agent for the treatment and/or prophylaxis of pediatric osteoporosis without causing bone growth disorder in a subject to be medicated. A pharmaceutical composition for the treatment and/or prophylaxis of pediatric osteoporosis contains an antibody or a functional fragment thereof which binds to Siglec-15 and has activity of suppressing formation of osteoclasts and/or bone resorption by osteoclasts.
    Type: Application
    Filed: June 29, 2018
    Publication date: April 16, 2020
    Applicants: NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Masahiko TAKAHATA, Dai SATO, Masahiro OTA, Tomohiro SHIMIZU, Chie FUKUDA, Eisuke TSUDA
  • Publication number: 20200113842
    Abstract: The tablet of the present invention is a tablet 1 having a cup portion 12 formed at least above or below a side portion 11, wherein the outer surface of the cup portion 12 includes first, second and third curved surfaces 12a, 12b and 12c having different curvatures R1, R2 and R3, the first curved surface 12a is at least continuous with the second curved surface 12b, the second curved surface 12b is continuous with the first curved surface 12a and the third curved surface 12c, and the third curved surface 12c is at least continuous with the second curved surface 12b.
    Type: Application
    Filed: June 26, 2018
    Publication date: April 16, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventor: Kazuhisa SEKINE
  • Patent number: 10603285
    Abstract: An object of the present invention is to provide [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate as a stabilized pharmaceutical solid preparation, and also to provide a method for preparing the stabilized pharmaceutical solid preparation. The object can be attained by a pharmaceutical solid preparation comprising [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate which is compound represented by the following formula (I) in combination with (i) one or two or more components selected from the group consisting of D-mannitol, lactose, corn starch, and crystalline cellulose, (ii) carmellose calcium, and (iii) colorants.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: March 31, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shinichiro Tajiri, Shinji Yoshinaga, Yurika Ozaki
  • Publication number: 20200085946
    Abstract: The present invention provides a pharmaceutical composition or a diagnostic composition targeting human fibroblast growth factor receptor 2 (hFGFR2).
    Type: Application
    Filed: November 19, 2019
    Publication date: March 19, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Chigusa YOSHIMURA, Reimi KAWAIDA, Kokichi HONDA
  • Publication number: 20200087321
    Abstract: The present invention relates to a compound or a pharmacologically acceptable salt thereof having excellent tissue non-specific alkaline phosphatase inhibitory activity. The present invention provides a compound represented by the formula (I) or a pharmacologically acceptable salt thereof.
    Type: Application
    Filed: December 22, 2017
    Publication date: March 19, 2020
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Shojiro Miyazaki, Masaharu Inui, Yasunobu Kurosaki, Yuko Yamamoto, Masanori Izumi, Kaori Soma, Anthony Pinkerton, Masamichi Kishida
  • Publication number: 20200080080
    Abstract: The present invention aims at establishing a molecular therapy for Alport syndrome. The present invention provides an oligonucleotide of 15-30 bp comprising a nucleotide sequence complementary to the cDNA of COL4A5 gene, wherein the oligonucleotide is capable of inducing skipping of an exon which has a truncating mutation found in COL4A5 gene in Alport syndrome patients and whose nucleotide number is a multiple of 3, a pharmaceutically acceptable salt thereof, or a solvate thereof. Also provided is a pharmaceutical drug comprising the above oligonucleotide, a pharmaceutically acceptable salt thereof, or a solvate thereof (therapeutic drug for Alport syndrome).
    Type: Application
    Filed: December 25, 2017
    Publication date: March 12, 2020
    Applicants: DAIICHI SANKYO COMPANY, LIMITED, NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY
    Inventors: Kazumoto IIJIMA, Kandai NOZU, Akemi SHONO, Makoto KOIZUMI, Yoshiyuki ONISHI, Kiyosumi TAKAISHI, Tomomi ADACHI
  • Publication number: 20200061031
    Abstract: [Problem] To provide a therapeutic agent and a therapeutic method for EGFR-TKI-resistant non-small cell lung cancer. [Solution] Provided are: a therapeutic agent that contains an anti-HER3 antibody-drug conjugate as an active ingredient, or a therapeutic method characterized by administering an anti-HER3 antibody-drug conjugate.
    Type: Application
    Filed: February 27, 2018
    Publication date: February 27, 2020
    Applicants: KINKI UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kimio YONESAKA, Kazuhiko NAKAGAWA, Kenji HIROTANI
  • Publication number: 20200062765
    Abstract: Provided is a novel and industrially useful method for producing a 3, 6-disubstituted imidazo[1, 2-b]pyridazine derivative. The present invention provides a method for producing a 3, 6-disubstituted imidazo[1, 2-b]pyridazine derivative, which uses 6-fluoroimidazo[1, 2-b]pyridazine as a starting material, while using an aromatic substitution reaction that utilizes C—H activation by means of palladium.
    Type: Application
    Filed: March 13, 2018
    Publication date: February 27, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Ryoji KOIKE, Yoshifumi HACHISU, Takafumi KITAWAKI, Shohei SHIRAISHI
  • Patent number: 10570109
    Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: February 25, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
  • Patent number: 10561628
    Abstract: An object of the present invention is to provide [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate as a stabilized pharmaceutical solid preparation, and also to provide a method for preparing the stabilized pharmaceutical solid preparation. The object can be attained by a pharmaceutical solid preparation comprising [(1R,5S,6S)-6-(aminomethyl)-3-ethylbicyclo[3.2.0]hept-3-en-6-yl]acetic acid monobenzenesulfonate which is a compound represented by the following formula (I) in combination with (i) one or two or more excipients, (ii) one or two or more disintegrants, and (iii) a specific antioxidant.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: February 18, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Shinichiro Tajiri, Jin Hisazumi, Shinji Yoshinaga, Hiroyuki Fujimori, Hiroaki Arai
  • Publication number: 20200039974
    Abstract: The present invention relates to a compound having RET kinase inhibiting action or a pharmaceutically acceptable salt thereof, useful in the treatment of diseases such as cancer. In particular a compound represented by the following general formula (I) as defined herein: (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 28, 2017
    Publication date: February 6, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Hiroaki Inagaki, Yoshihiro Shibata, Hidenori Namiki, Hideaki Kageji, Kiyoshi Nakayama, Yasuyuki Kaneta
  • Publication number: 20200040019
    Abstract: There is a need for a new antibiotic having a novel mechanism of action, which exhibits strong antibacterial activity not only against sensitive bacteria, but also against resistant bacteria thereof, and at the same time possess excellent solubility and safety profile amenable to human use. As a result of intensive research, the present inventors have found that N-phosphonoxymethyl prodrugs of hydroxyalkyl thiadiazole derivatives represented by general formula (I), a regioisomer, a stereoisomer, or a pharmaceutically acceptable salt thereof possess excellent solubility and safety profile for use in human for the treatment of bacterial infectious diseases.
    Type: Application
    Filed: March 13, 2018
    Publication date: February 6, 2020
    Applicant: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Manoj Kumar Khera, Naresh Chintaman Dumbre, Pasha Khan
  • Patent number: 10550198
    Abstract: The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.
    Type: Grant
    Filed: July 24, 2018
    Date of Patent: February 4, 2020
    Assignee: DAIICHI SANKYO COMPANY, LIMITED
    Inventors: Kazuki Satoh, Kazuki Hirahara, Ichiro Watanabe, Masato Amano
  • Patent number: 10550154
    Abstract: Disclosed are compositions and method related to variants of SPINK2 that bind to targets other than an endogenous target of SPINK2. In one embodiment, a peptide is provided that comprises the amino acid sequence SEQ ID NO: 1. In further embodiments, an amino acid sequences encoded by nucleotide positions 4 to 42 and/or nucleotide positions 94 to 189 in the nucleotide sequence of SEQ ID NO: 14 flank the amino terminus and the carboxyl terminus, respectively, of the amino acid sequence. In another embodiment, a peptide is provided that comprises an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 1 in which a conservative substitution, deletion, addition and/or insertion of 1 to 5 (inclusive) amino acids has occurred at amino acids other than the 1st Xaa to the 12th Xaa counting from the amino terminus.
    Type: Grant
    Filed: August 7, 2013
    Date of Patent: February 4, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Daisuke Nishimiya, Ryuji Hashimoto
  • Publication number: 20200030414
    Abstract: The present invention provides a therapeutic agent for failure-to-thrive or short stature which contains C-type natriuretic peptide (CNP) or a CNP derivative as an active ingredient, reduces adverse reactions, and exhibits excellent efficacy, and a method for treating failure-to-thrive or short stature.
    Type: Application
    Filed: January 23, 2018
    Publication date: January 30, 2020
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Naomi Morozumi, Mayumi Furuya, Toshimasa Jindo, Yasuyuki Abe, Shiuhei Mieda, Akiko Ohno